Research programme: influenza therapeutic - onepharm

Drug Profile

Research programme: influenza therapeutic - onepharm

Alternative Names: OMP-3001

Latest Information Update: 11 Nov 2009

Price : $50

At a glance

  • Originator onepharm
  • Developer Minophagen; onepharm
  • Class Carbohydrates; Triterpenes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 11 Nov 2009 Discontinued for Influenza virus infections in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top